SAR3419 is a TAP compound that consists of a CD19-binding antibody developed by ImmunoGen with one of our potent cell-killing agents, DM4, attached using one of our engineered linkers. We licensed it to Sanofi preclinically as part of a broader collaboration.
In Phase I testing, SAR3419 demonstrated activity across an array of CD19+ non-Hodgkin's lymphoma (NHL) histological subtypes. It also was active against both rituximab-refractory and rituximab-responsive disease and was generally well tolerated. Findings with the recommended Phase II dosing schedule were reported at the American Society of Clinical Oncology annual meeting in June 2012.
SAR3419 is in Phase II testing to evaluate the compound for diffuse large B-cell lymphoma (DLBCL, which is the most common type of NHL) and for B-cell acute lymphoblastic leukemia (B-ALL).
Back to Pipeline
Last updated July 30, 2012